Business
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team WESTLAKE VILLAGE, Calif., March 25, 2025
About this update from Neonc Technologies Holdings, Inc.
[{"type":"text","content":"Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team\nWESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced the appointment of Dr. Steven L. Giannotta, a distinguished neurosurgeon and former Chair of Neurological Surgery at the University of Southern California (USC), to its Board of Directors. Dr. Giannotta brings over four decades of expertise in cerebrovascular and cranial base surgery, with contributions to cerebral blood flow research, ischemia prevention, and innovative surgical techniques. “Steven’s extensive background in neurological surgery, especially his leadership in advancing both research and surgical techniques for cerebrovascular diseases, will be invaluable to our Company,” said Dr. Thomas Chen, CEO of NeOnc. “We look forward to having his expertise and visionary perspective shape our progress as we continue to advance our mission of pursuing innovative solutions that enhance patient care, bring hope, and extend lives.\" Dr. Giannotta joined the USC Department of Neurosurgery in 1980, and has since become internationally recognized for his groundbreaking work in cerebrovascular disease, including pioneering \"hyperdynamic therapy\" as a clinical approach to combat cerebral vasospasm. His research interests encompass cerebral blood flow, ischemia, and the impact of ethnic differences on cerebrovascular disorders. Dr. Giannotta's clinical achievements include performing over 1,000 intracranial aneurysm surgeries and developing a comprehensive, multidisciplinary approach to complex cerebrovascular conditions. \"I am thrilled to be a part of NeOnc's Board of Directors,” said Dr. Giannotta. \"I have spent my entire professional career on development of dynamic therapies, and believe NeOnc is on the right path with the same mission.” \"Dr. Giannotta’s dedication to improving patient outcomes and pioneering innovative approaches aligns seamlessly with our core values,” said Amir Heshmatpour, Executive Chairman of NeOnc. “We believe his wealth of experience in managing complex cerebrovascular conditions will greatly enhance our ability to deliver cutting-edge solutions in neurosurgical ca...